Markus Wenk’s current research is determination of natural variation of circulating metabolites beyond well-known examples such as cholesterol. This knowledge will form a conceptual basis for integration of molecular phenotyping into precision health and medicine. In that context he and his team has initiated and are currently coordinating global trials aimed at technology harmonization and determination of biological reference ranges. Markus Wenk is a thought leader in mass spectrometry based lipidomics. He established the Singapore lipidomics incubator (SLING) and more recently the ‘NUS-Agilent Hub for translation and capture’, a $28 million facility for translation of biochemical innovation and techniques to clinical testing.
Clinical & Research Tools Showcase:
National University of Singapore, a leading global university, shaping the future.
Partnership Hub for Clinical Translation of Technology
Introduction to partnership model from academic R&D laboratories with downstream reach to hospital-based laboratory medicine.